Viking Therapeutics Releases Corporate Presentation Highlighting Advancements in Obesity and Metabolic Disease Drug Pipeline

Reuters

2025/10/02

<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Releases Corporate Presentation Highlighting Advancements in Obesity and Metabolic Disease Drug Pipeline

Viking Therapeutics Inc. has released a corporate presentation outlining updates on its clinical pipeline focused on metabolic and endocrine diseases. The company highlighted progress across several programs, including VK2735, a dual GLP-1/GIP agonist for obesity currently in Phase 3 clinical trials, and an oral formulation of VK2735, which has completed a Phase 2a study. An amylin agonist for obesity is expected to enter clinical development with an IND planned for the fourth quarter of 2025. Additional programs include VK2809, a selective thyroid receptor-β agonist for MASH, which recently completed a successful Phase 2b trial, and VK0214, another thyroid receptor-β agonist for X-ALD, with positive results from a Phase 1b study. You can access the full presentation through the link below. [Full Presentation](https://docs.publicnow.com/1407985E4D5081D9553ABD929FE96930F35D20E6)

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2572522551"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572522551\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572522551?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 02:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572522551","market":"nz","top_or_hot":-1,"title":"Viking Therapeutics Releases Corporate Presentation Highlighting Advancements in Obesity and Metabolic Disease Drug Pipeline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Releases Corporate Presentation Highlighting Advancements in Obesity and Metabolic Disease Drug Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viking Therapeutics Inc. has released a corporate presentation outlining updates on its clinical pipeline focused on metabolic and endocrine diseases. The company highlighted progress across several programs, including VK2735, a dual GLP-1/GIP agonist for obesity currently in Phase 3 clinical trials, and an oral formulation of VK2735, which has completed a Phase 2a study. An amylin agonist for obesity is expected to enter clinical development with an IND planned for the fourth quarter of 2025. Additional programs include VK2809, a selective thyroid receptor-β agonist for MASH, which recently completed a successful Phase 2b trial, and VK0214, another thyroid receptor-β agonist for X-ALD, with positive results from a Phase 1b study. You can access the full presentation through the link below. [Full Presentation](https://docs.publicnow.com/1407985E4D5081D9553ABD929FE96930F35D20E6)\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viking Therapeutics Releases Corporate Presentation Highlighting Advancements in Obesity and Metabolic Disease Drug Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViking Therapeutics Releases Corporate Presentation Highlighting Advancements in Obesity and Metabolic Disease Drug Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-02 02:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Releases Corporate Presentation Highlighting Advancements in Obesity and Metabolic Disease Drug Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viking Therapeutics Inc. has released a corporate presentation outlining updates on its clinical pipeline focused on metabolic and endocrine diseases. The company highlighted progress across several programs, including VK2735, a dual GLP-1/GIP agonist for obesity currently in Phase 3 clinical trials, and an oral formulation of VK2735, which has completed a Phase 2a study. An amylin agonist for obesity is expected to enter clinical development with an IND planned for the fourth quarter of 2025. Additional programs include VK2809, a selective thyroid receptor-β agonist for MASH, which recently completed a successful Phase 2b trial, and VK0214, another thyroid receptor-β agonist for X-ALD, with positive results from a Phase 1b study. You can access the full presentation through the link below. [Full Presentation](https://docs.publicnow.com/1407985E4D5081D9553ABD929FE96930F35D20E6)\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VKTX","symbol_name":"Viking Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDLb67Z1X:1","article_id":"2572522551","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572522551","pubTimestamp":1759342639,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VKTX":"Viking Therapeutics, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4599":"减肥药","BK4588":"碎股"},"translate_title":"Viking Therapeutics发布公司演示文稿，重点介绍肥胖和代谢疾病药物管道的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":0.9},"content_text":"Viking Therapeutics Releases Corporate Presentation Highlighting Advancements in Obesity and Metabolic Disease Drug Pipeline\n    \n\n        Viking Therapeutics Inc. has released a corporate presentation outlining updates on its clinical pipeline focused on metabolic and endocrine diseases. The company highlighted progress across several programs, including VK2735, a dual GLP-1/GIP agonist for obesity currently in Phase 3 clinical trials, and an oral formulation of VK2735, which has completed a Phase 2a study. An amylin agonist for obesity is expected to enter clinical development with an IND planned for the fourth quarter of 2025. Additional programs include VK2809, a selective thyroid receptor-β agonist for MASH, which recently completed a successful Phase 2b trial, and VK0214, another thyroid receptor-β agonist for X-ALD, with positive results from a Phase 1b study. You can access the full presentation through the link below. [Full Presentation](https://docs.publicnow.com/1407985E4D5081D9553ABD929FE96930F35D20E6)\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}